Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer

Colon Cancer Stage III Clinical Trial

Official title:
Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer: A Pilot, Randomized, Open Label, Controlled Study.

Status Withdrawn

Clinical Trial Summary

chlorpromazine displays a series of remarkable bio-molecular effects in cancer cells, as inhibition of cell growth, nuclear aberrations, inhibition of the phosphoinositide 3-kinase/mammilian target of rapamycin (PI3K/mTOR) axis, induction of cytotoxic autophagy, inhibition of glutamate and DRD2 receptors. This study will evaluate the addition of chlorpromazine to the first-line therapeutic protocol in colon cancer stage III.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05433402
Study type	Interventional
Source	Sadat City University
Contact
Status	Withdrawn
Phase	Phase 1/Phase 2
Start date	July 20, 2022
Completion date	September 30, 2022

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04907643` - Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes	N/A
Completed	`NCT00309530` - Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C	Phase 3
Completed	`NCT04342676` - Lymph Node Ratio and Kras Mutation in R Colon Cancer	Phase 3
Enrolling by invitation	`NCT05179889` - Adjuvant mFOLFIRINOX for High-risk Stage III Colon Cancer	Phase 2/Phase 3
Recruiting	`NCT06108310` - ArTificial inTelligence-based RAdiogenomics in Colon Tumors
Withdrawn	`NCT05310565` - The Effects of Chiropractic in Adults With Colon Cancer	N/A
Not yet recruiting	`NCT04488159` - Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer	Phase 3
Recruiting	`NCT05194878` - Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers	Phase 3